Skip to main content

Table 3 Sample size per arm for a hypothetical clinical trial using different cognitive outcome measures

From: Cognitive composites for genetic frontotemporal dementia: GENFI-Cog

Outcome measures

C9orf72

GRN

MAPT

ES 10%

ES 20%

ES 40%

ES 10%

ES 20%

ES 40%

ES 10%

ES 20%

ES 40%

Cognitive composite scores

Average composite

306

76

19

27

7

2

124

31

8

Weighted composite

214

53

13

53

13

3

90

23

6

Language

Camel and Cactus Test

4946

1237

309

292

73

18

357

89

22

Boston Naming Test

1109

277

69

213

53

13

223

56

14

Category fluency

1584

396

99

781

195

49

400

100

25

Attention and mental processing speed

Digit span forward

13,0210

32,553

8138

2677

669

167

17,773

4443

1111

Trail Making Test – part A

2272

568

142

45

11

3

69

17

4

Digit symbol

254

64

16

925

231

58

80

20

5

D-KEFS CWIT – colour naming

866

216

54

502

126

31

66

17

4

D-KEFS CWIT – word naming

19,224

4806

1202

3310

828

207

150

37

9

Executive functioning

Digit span backward

1724

431

108

840

210

52

26,218

6555

1639

Trail Making Test – part B

1275

319

80

25

6

2

81

20

5

D-KEFS CWIT – ink naming

61

15

4

70

17

4

26

7

2

Phonemic fluency

558

139

35

2229

557

139

161

40

10

Visuoconstruction

Benson figure copy

5911

1478

369

2119

530

132

6,282,036

1,570,509

392,627

Memory

Benson figure recall

1044

261

65

657

164

41

7611

1903

476

FCSRT free recall

1302

326

81

294

74

18

521

130

33

FCSRT total recall

1020

255

64

477

119

30

524

131

33

FCSRT delayed free recall

606

152

38

767

192

48

261

65

16

FCSRT delayed total recall

358

89

22

193

48

12

681

170

43

Social cognition

Facial Emotion Recognition Test

7570

1892

473

7805

1951

488

147

37

9

  1. The sample size per arm was estimated as n = (1 − ρ^2)(2σ^2)/δ^2 f(α,β), where ρ is the correlation between baseline and follow-up measures of the outcome, σ is the standard deviation of the outcome in the CDR® plus NACC-FTLD 0.5 group, δ is the treatment effect (effect size multiplied by the difference in mean between CDR® plus NACC-FTLD 0.5 and 1 group), α is the significance level (0.05), and 1 − β is the power to detect a treatment effect (80%)
  2. Abbreviations: C9orf72 chromosome 9 open reading frame 72, GRN progranulin, MAPT microtubule-associated protein tau, ES effect size as a proportion of the difference between the outcome in the CDR® plus NACC-FTLD 0.5 group and the outcome in the CDR® plus NACC-FTLD 1 group, D-KEFS CWIT Delis-Kaplan Executive Function System Colour-Word Interference Test, FCSRT Free and Cued Selective Reminding Test